Status:
COMPLETED
Recombinant Human Leptin Therapy Effects on Insulin Action
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
Amgen
National Institutes of Health (NIH)
Conditions:
Type Two Diabetes Mellitus
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
Leptin therapy improves insulin sensitivity in people with leptin-deficiency but it is not known whether it improves insulin action in persons who are not leptin deficient. The purpose of the present ...
Detailed Description
Leptin therapy improves insulin sensitivity in people with leptin-deficiency but it is not known whether it improves insulin action in persons who are not leptin deficient. The purpose of the present ...
Eligibility Criteria
Inclusion
- diagnosed with type 2 diabetes for less than ten years
- Body mass index 25 - 40
- hemoglobin A1C 7.5% - 12.0%
- fasting blood glucose between 90 and 240mg/dL
Exclusion
- smoking
- pregnancy
- diabetes medications
- regular exercise (more than 3 hours per week)
- uncontrolled hypertension: systolic blood pressure greater than 160 or diastolic blood pressure greater than 95
Key Trial Info
Start Date :
August 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2000
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01207934
Start Date
August 1 1998
End Date
July 1 2000
Last Update
July 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110